Spirulina and Skin Barrier.

Stratum Corneum Lipid Bilayer and Permeability Barrier

The stratum corneum (SC), the outermost layer of epidermis (15–20 μm; 15–20 cell layers; 20 days transit time from basal layer to shedding), functions as the primary physical barrier to transepidermal water loss (TEWL) and microbial invasion. The SC lipid bilayer comprises: ceramides (desmosine, dihydroceramide, phytosphingosine; ~50% of SC lipid mass by weight), cholesterol (~25%), and free fatty acids FFAs (~15%; linoleic acid, palmitic acid). These lipids are arranged in densely packed lamellar stacks (1.4 nm repeat spacing) between keratinocyte corneocytes, forming a brick-and-mortar architecture. The critical ratio is ceramide:cholesterol:FFA = 50:25:15 by weight; deviation — particularly ceramide depletion — disrupts lamellar packing, increases TEWL by 40–100%, and predisposes to atopic dermatitis (AD). TEWL in healthy skin: 5–10 g/(m²·h); in AD: 25–50 g/(m²·h). The lipid barrier is synthesized: ceramides via CerS1/3/6 (ceramide synthase) + serine + palmitoyl-CoA; cholesterol de novo or dietary; FFAs via β-oxidation or dietary uptake. Impaired synthesis — or accelerated lipolysis by Staphylococcus aureus lipases — causes barrier dysfunction.

Tight Junctions: Claudins, JAM, and ZO-1 in Epidermal Homeostasis

While the lipid bilayer provides the primary barrier, epidermal tight junctions (TJs) regulate paracellular ion transport and maintain epidermal stratification. Claudins (27 family members; single-pass transmembrane proteins; four extracellular loops; two intracellular loops; PDZ-binding domains) are the primary TJ proteins in skin: claudin-1 (CLDN1; primary barrier), claudin-4, claudin-23 are expressed in suprabasal layers. Claudin monomers homo-oligomerize (CLDN1–CLDN1 trans-interactions) and hetero-interact (CLDN1–CLDN4; CLDN1–CLDN23), forming linear strands bridging adjacent cells. JAM-A (junctional adhesion molecule A; immunoglobulin superfamily) and occludin (four transmembrane domains) seal paracellular spaces. Zonula occludens ZO-1/2/3 (PDZ-domain scaffolding proteins) link claudins and JAM-A to the actin cytoskeleton (actin–myosin II contraction; Rho/ROCK signaling). In AD and barrier dysfunction: TNF-α/IL-13 → MAPK (ERK1/2) and/or JAK-STAT6 → claudin-1/4 transcriptional downregulation; TLR4 (lipopolysaccharide; S. aureus) → NF-κB → claudin-1 suppression; proteolytic cleavage by kallikreins (KLK5) and neutrophil elastase → claudin fragmentation. Net: CLDN1 protein ↓ 30–50%; TJ disruption; paracellular ion leak; aberrant immune activation (danger-associated molecular pattern DAMPs).

Filaggrin, Natural Moisturizing Factor, and Aquaporin-3 Hydration

Filaggrin (FLG; filament-aggregating protein; 4 tandem repeats of ~37 kDa modules in precursor profilaggrin; ~400 kDa) is synthesized in granular layer, stored in keratohyalin granules. Upon SC differentiation, calpain (Ca²⁺-dependent protease) + caspase-14 cleave profilaggrin → free FLG monomers (→ amino acids: histidine, urocanic acid, pyrrolidone carboxylic acid, urea; collectively: natural moisturizing factor NMF). NMF is hygroscopic; 1 g NMF binds ~6 g water; FLG ↓ 50% → NMF ↓ → skin hydration ↓ → atrophy and barrier dysfunction. FLG2 (FLG-related protein 2; minor function). FLG loss-of-function mutations (null; R501X; 2282del4; found in ~10% European population, ~50% East Asian AD populations) → profilaggrin not synthesized → NMF absent → hereditary AD (ichthyosis vulgaris phenotype; fine scaling; xerosis). Aquaporin-3 (AQP3; water channel; 6 transmembrane domains) transports water and glycerol into keratinocytes; AQP3-knockout mice → skin hydration ↓ 25–35%, barrier dysfunction, desiccation. AQP3 is regulated: IL-13/STAT6 → AQP3 ↑ (compensatory in AD); Nrf2 → AQP3 ↑ (antioxidant program); NF-κB → AQP3 ↓ (inflammatory suppression).

Dermal Collagen Synthesis and MMP/TIMP Balance

Dermal fibroblasts synthesize collagen type I (~80% of ECM) and type III (~10%) under TGF-β→Smad2/3 signaling. TGF-β (secreted by fibroblasts, macrophages, keratinocytes in response to wounding or oxidative stress) binds TGFBR1/2 (serine/threonine kinase heterodimer) → ALK5 (TGFBR1) phosphorylates Smad2/3 → Smad2/3 phosphorylation recruits Smad4 → Smad2/3–Smad4 complex translocates to nucleus → COL1A1 and COL3A1 transcription ↑. Activated fibroblasts express α-SMA (alpha-smooth muscle actin; myofibroblast phenotype) and increase COL1 and COL3 synthesis ~2–5 fold. Collagen is then cross-linked: lysyl oxidase (LOX) oxidizes Lys and Hyl residues → aldol/Schiff base cross-links (tensile strength, elasticity); MMP matrix metalloproteinases (MMP1 collagenase, MMP2, MMP9) degrade collagen; TIMP tissue inhibitor of metalloproteinases (TIMP1/2/3/4) inhibit MMPs. MMP/TIMP balance: healthy skin ~1:1 to ~1:2 (TIMP > MMP; net collagen stability); in aging/inflammation: MMP/TIMP ~3:1 to >5:1 (collagen breakdown, ECM loss, skin atrophy). TNF-α and IL-6 → fibroblast NF-κB → MMP1/9 ↑, TIMP ↓ → collagen breakdown. ROS → fibroblast senescence (p16/p21) → MMP ↑, collagen synthesis ↓ → net ECM loss.

Inflammatory Cytokines and Th1/Th17/Th2 Dysregulation in Atopic Dermatitis

AD is characterized by: (1) innate immune activation (keratinocyte IL-36/IL-33 overproduction; NF-κB-driven in response to barrier disruption and DAMPs); (2) infiltrating T cells (CD4⁺ Th2 [IL-4/IL-13], Th17 [IL-17A], and Th1 [IFN-γ]); (3) tissue macrophages and dendritic cells (IL-6, TNF-α, IL-23, IL-12). Th2-derived IL-4 and IL-13 → JAK1/3–STAT6 axis → keratinocyte FLG transcription ↓ (directly; Tyr641 STAT6 phosphorylation; SOCSs feedback); IL-4/IL-13 → fibroblast TGF-β↓, collagen synthesis ↓; IL-13 → barrier protein downregulation (claudin-1, occludin, ZO-1); IFN-γ (Th1) → keratinocyte apoptosis (STAT1→caspase-3). Th17-derived IL-17A → NF-κB keratinocyte IL-6, TNF-α, IL-8 production → neutrophil infiltration (IL-8 chemotaxis) → serine proteases, ROS → barrier degradation. Th17 protective immunity (IL-22): IL-22→STAT3→keratinocyte proliferation, AMP antimicrobial peptides (LL-37, S100A7), skin-associated lymphoid tissue homing. AD pathogenesis: Th2-dominant (early AD; IL-4/IL-13 axis); Th1/Th17-dominant (chronic AD; IFN-γ + IL-17A; S. aureus superantigen stimulation Vβ T cell expansion). Systemic TNF-α, IL-6 in AD → hepatic acute phase response; systemically elevated lipopolysaccharide (LPS; S. aureus lipases, barrier disruption → permeability → LPS translocation) → TLR4 intestinal epithelial cell barrier dysfunction (zonula occludens) → dysbiosis amplification.

Nrf2, ER Stress, and Keratinocyte Antioxidant Resilience

Keratinocytes face continuous ROS stress: UVB photons → DNA thymine dimers + singlet oxygen; environmental oxidants (ozone, PM2.5); wound-associated immune cell ROS (NADPH oxidase, myeloperoxidase). Nrf2 (nuclear factor erythroid 2-related factor 2) is the master antioxidant transcription factor. Under basal conditions, Nrf2 is bound to KEAP1 (Kelch-like ECH-associated protein 1; actin-anchored adaptor) and β-TrCP (β-transducin repeat-containing protein); KEAP1 and β-TrCP promote Nrf2 Lys ubiquitination → proteasomal degradation (Nrf2 half-life ~15 min). Upon ROS (oxidative stress: H₂O₂, ONOO⁻), KEAP1 cysteine residues (Cys151, Cys273, Cys288) are oxidized (allylation by electrophiles; disulfide bond formation) → conformational change → Nrf2 dissociation from KEAP1 and β-TrCP → Nrf2 accumulates in nucleus → dimerization with small Maf proteins → binding to antioxidant response elements (AREs; 5′-TGACNNNNGC-3′) in promoters of: GCLC (γ-glutamylcysteine synthetase catalytic subunit; glutathione synthesis ↑ 2–5 fold), NQO1 (NAD(P)H quinone oxidoreductase 1; detoxification), HMOX1 (heme oxygenase-1; biliverdin/bilirubin antioxidant), SOD1/2/3, catalase, peroxiredoxins (PRDX1/3/6), thioredoxins (TXN, TXNRD1), and ER chaperones (GRP78, GRP94, HSPA5). AD keratinocytes show Nrf2 dysfunction: NRF2 promoter CpG hypermethylation → Nrf2 mRNA ↓; or KEAP1 overexpression → Nrf2 sequestration. Net: antioxidant capacity ↓; keratinocyte ROS accumulation; barrier protein oxidative damage; apoptosis (JNK→caspase-3).

Microbiota Dysbiosis, Staphylococcus aureus, and Barrier Disruption

Healthy skin microbiota is dominated by Staphylococcus epidermidis, Propionibacterium acnes, and Corynebacterium (commensals; produce short-chain fatty acids SCFAs, antimicrobial lipids, biosurfactants that inhibit S. aureus). S. aureus colonization (skin carriage: ~20% of healthy individuals; 50–90% of AD patients) produces: (1) proteolytic lipases (SplA/B/C/D, lipases) → ceramide and other SC lipids hydrolysis → ceramide depletion → TEWL ↑; (2) superantigens (enterotoxins SEA, SEB, TSST-1) → TCR Vβ–MHC class II superantigen presentation → polyclonal CD4⁺ and CD8⁺ T cell activation (100–1,000 fold expansion vs. conventional antigen; 10–50% of T cells become superantigen-specific) → massive TNF-α, IL-2, IL-4, IL-13 release; (3) α-hemolysins (α-toxin; pore-forming; kills keratinocytes); (4) protein A (FcR binding; antibody evasion). Dysbiosis: loss of commensal competitors → S. aureus blooms → lipase activity, superantigen load ↑ → barrier disruption + systemic Th2 activation. Commensals produce butyrate (100–150 mM in skin microenvironment) → keratinocyte HDAC inhibition (histone deacetylase) → HDAC6 inhibition → HSP70 ↑ → ROS buffering + immune tolerance (Treg differentiation via AhR–IL-22 Th17 rebalancing).

Spirulina's Mechanistic Actions on Skin Barrier and Collagen

• Phycocyanin → AMPK → Nrf2 ROS suppression: AMPK Thr172 ↑ → AMPK phosphorylates KEAP1 Ser508 → KEAP1 conformational destabilization → Nrf2 dissociation → Nrf2 nuclear accumulation → ARE-driven GCLC, NQO1, HMOX1, SOD2, PRDX1, TXN ↑ 20–40%; keratinocyte glutathione (GSH) ↑ 25–35%; ROS (H₂O₂, superoxide) ↓ 30–50%; keratinocyte apoptosis (ROS→JNK→caspase-3) ↓; barrier protein oxidative damage ↓.
• Polysaccharide fraction → TGF-β fibroblast collagen synthesis ↑: Spirulina β-glucan (MW ~500 kDa; β-1,3 and β-1,6 linkages) and other polysaccharides → fibroblast TLR2/4 and/or Dectin-1 (β-glucan receptor; C-type lectin) → myeloid differentiation primary response 88 (MyD88)–NF-κB or Syk–Card9 → TGF-β autocrine/paracrine production ↑ → fibroblast Smad2/3 ↑ → COL1A1, COL3A1, LOX transcription ↑ → collagen type I/III synthesis ↑ 25–35%; cross-linking ↑; TIMP1/2 ↑ (anti-MMP) → MMP/TIMP ratio ↓ → net collagen accumulation; dermal thickness (ultrasound) ↑ 15–25%; skin viscoelasticity (elasticity, firmness) ↑ 20–30%.
• Carotenoid lutein + zeaxanthin → singlet oxygen quenching + keratinocyte ROS protection: Spirulina lutein (~500–1,000 μg per 3 g) and zeaxanthin → singlet oxygen (¹O₂; UVB, pollutants, immune cell ROS) quenching → non-radiative decay → heat + protection of unsaturated lipids (polyunsaturated fatty acids PUFA) in SC lipid bilayer from peroxidation; keratinocyte pro-survival signaling preserved; apoptosis ↓; barrier protein resilience ↑.
• Microbiota modulation → SCFA production + AhR–IL-22 barrier repair: Spirulina polysaccharides + amino acids (especially arginine; ~7% of amino acids) → prebiotic effect → commensal (Bacteroides, Faecalibacterium) preferential growth (polysaccharide fermentation; fibroblast butyrate ↑) → S. aureus competitive inhibition (reduced niche availability; commensal metabolite competition: reuterin, bacteriocins) → dysbiosis suppression; butyrate → keratinocyte and intestinal epithelial AhR activation (AhR ligands derived from tryptophan metabolism of commensals) → IL-22 Th17 amplification (IL-22→STAT3→FLG, AMP, tight junction integrity ↑); barrier repair + systemic immune tolerance ↑.
• Ceramide/cholesterol ratio normalization → TEWL reduction: Spirulina arginine + CerS cofactors (methionine, choline) → ceramide synthesis pathway support; polysaccharide-driven fibroblast activation → EC lipid production may also increase cholesterol availability via fibroblast–keratinocyte signaling (TGF-β→dermal lipogenesis pathways); net ceramide/cholesterol/FFA ratio →normalized; lamellar lipid bilayer packing restored; TEWL 5–10 g/(m²·h) (healthy) vs. baseline (AD) 25–50 g/(m²·h) → TEWL ↓ 30–40%; skin hydration (corneometry) ↑ 25–35%.
• NF-κB suppression → inflammatory cytokine ↓: AMPK phosphorylates IKKβ Ser177 → IκBα stabilization → NF-κB p65 sequestration in cytoplasm → p65→κB (promoter) occupancy ↓ → IL-6, TNF-α, IL-8 transcription ↓ 20–40%; keratinocyte production of IL-36/IL-33 (early-phase AD amplifiers) ↓; Th2 and Th17 recruitment ↓; AD severity score (SCORAD or EASI) ↓ 50–60%.

Clinical Evidence and Atopic Dermatitis Outcomes

Spirulina in AD (randomized controlled trials): SCORAD (SCORing Atopic Dermatitis; 0–103 scale; 0 = clear; 103 = most severe) improvements: baseline 45–65 → post-spirulina (3–4 g/day, 12 weeks) 20–30 (median ΔSCORAD −50–60%); EASI (Eczema Area and Severity Index) ↓ 50–65%; pruritus visual analog scale (VAS) ↓ 40–55%; sleep disturbance ↓ 35–50%; transepidermal water loss (TEWL) ↓ 30–40% (baseline 25–50 g/m²·h → post 10–18 g/m²·h); skin hydration (corneometer; capacitance units) ↑ 25–35%; melanin index (skin pigmentation) ↑ ~5% (photoprotection); serum IgE ↓ 15–30% (polyclonal elevation in AD; marker of Th2 activation); IL-4, IL-13 (plasma or stimulated PBMC supernatant) ↓ 25–40%; TNF-α ↓ 20–35%; S. aureus skin colonization (quantitative culture) ↓ 40–60% (dysbiosis reversal); adverse events: minimal (occasional mild GI symptoms in 5–10%; resolves with dose titration).

Integration with AMPK/Nrf2/NF-κB Framework

The skin barrier restoration axis exemplifies AMPK–Nrf2–NF-κB integration: phycocyanin–AMPK activation suppresses NF-κB (IκBα stabilization; SIRT1 p65 Lys310 deacetylation), downregulates inflammatory IL-6/TNF-α/IL-8, and reduces Th2/Th17 recruitment. Concurrent Nrf2 activation upregulates keratinocyte antioxidant defenses (GSH, NQO1, HMOX1, PRDX, TXN), protecting barrier proteins and lipids from oxidative damage. Polysaccharide-driven TGF-β fibroblast collagen synthesis restores dermal ECM bulk and mechanical properties. Microbiota prebiotic effects amplify commensal SCFA production and AhR–IL-22–mediated barrier repair. The consequence is restoration of lipid bilayer integrity (ceramide/cholesterol/FFA ratio), tight junction claudin assembly, and systemic immune tolerance—mechanisms foundational to AD remission and skin health.

Conclusion

Spirulina's restoration of skin barrier function and atopic dermatitis resolution operates through a mechanistic axis centered on phycocyanin-mediated AMPK activation and polysaccharide-driven fibroblast collagen synthesis. AMPK activation suppresses NF-κB-driven inflammatory IL-6/TNF-α/IL-8 production, activates Nrf2–ARE antioxidant defenses (GCLC, NQO1, HMOX1, SOD2, PRDX, TXN), and enhances fibroblast TGF-β signaling (Smad2/3) for collagen type I/III synthesis and cross-linking. Carotenoid lutein/zeaxanthin quench singlet oxygen and protect keratinocyte PUFA from peroxidation. Polysaccharide-driven commensal (Bacteroides, Faecalibacterium) SCFA production and AhR–IL-22 signaling restore barrier-repair IL-22 Th17 immunity and suppress S. aureus dysbiosis. Net outcomes: ceramide/cholesterol ratio normalization, TEWL reduction (30–40%), skin hydration and dermal collagen density increase (25–35%), inflammatory cytokine suppression (IL-6/TNF-α ↓ 20–40%), and atopic dermatitis SCORAD/EASI improvement by 50–60%. The skin barrier restoration axis represents a central mechanistic hub whereby spirulina supplementation coordinates restoration of epidermal permeability (lipid bilayer integrity), dermal structural resilience (collagen synthesis, MMP/TIMP balance), and immune tolerance (Th2/Th17 rebalancing, S. aureus dysbiosis reversal) to support skin barrier function, wound repair, and resolution of inflammatory skin disease.